twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2007
vol. 109
 
Share:
Share:
abstract:
Original paper

The results of wet AMD treatment by intravitreal injections – preliminary report

Anna Okruszko
1
,
Anna I. Borucka
1, 2
,
Magdalena Ulińska
1, 2
,
Jerzy Szaflik
1

  1. Z Katedry i Kliniki Okulistyki II Wydziału Lekarskiego Akademii Medycznej w Warszawie
  2. Z Centrum Okulistycznego „Laser” w Warszawie
Klinika Oczna 2007, 109 (4): 389-393
Online publish date: 2007/12/20
View full text Get citation
 
Age-related macular degeneration (AMD) is the leading cause of irreversible, severe loss of vision in the developed countries.

Age-related macular degeneration (AMD) is the leading cause of irreversible, severe loss of vision in the developed countries.

One of the modern methods of treatment in neovascular form of AMD are repeated intravitreal injections of ranibizumab (Lucentis®). Ranibizumab is a recombinant, humanized, monoclonal antibody that neutralizes all biologically active forms of vascular

endothelial growth factor A (VEGF-A).

The aim of the study was to analyze the results of intravitreal ranibizumab injections in wet AMD patients. There were 57 patients enrolled in the study. 87% of them avoided any loss of visual acuity and 47.3% gained at least one line at visual acuity chart. Authors conclude that treatment with repeated intravitreal injections of ranibizumab is effective in neovascular form of AMD.
keywords:

age-related macular degeneration, AMD, choroidal neovascularization, ranibizumab, intravitreal injection

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.